This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
Current Hematologic Malignancy Reports Open Access 13 February 2023
-
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Stem Cell Research & Therapy Open Access 18 December 2021
-
Chronic myeloid leukemia stem cells
Leukemia Open Access 24 May 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ren R . Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172–183.
Sloma I, Jiang X, Eaves AC, Eaves CJ . Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823–1833.
Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872–884.
Mahon FX, Etienne G . Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res 2014; 20: 310–322.
Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013; 27: 1520–1526.
Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010; 107: 16280–16285.
Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 2014; 123: 3951–3962.
Nievergall E, Ramshaw HS, Yong ASM, Biondo M, Busfield SJ, Vairo G et al. Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014; 123: 1218–1228.
Florian S, Sonneck K, Hauswirth AW, Krauth M-T, Schernthaner G-H, Sperr WR et al. Detection of molecular targets on the surface of CD34+/CD38– stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207–222.
Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74: 2669–2676.
Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2014; 94: 243–250.
Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232–238.
Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096–2102.
Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A et al. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia 2011; 26: 977–984.
Acknowledgements
We thank all investigators of the NordCML006 study for sharing samples and clinical data. This work was supported by the Swedish Cancer Society, the Swedish Children’s Cancer Foundation, the Swedish Research Council, the Inga-Britt and Arne Lundberg Foundation, the Gunnar Nilsson Cancer Foundation, the Medical Faculty of Lund University, the strategic research program BioCARE, the Finnish Cancer Institute and the Academy of Finland.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
MJ and TF are cofounders and have equity ownership in Cantargia AB (Ideon Medical Village, Lund, Sweden) formed with Lund University Bioscience AB. JR has stock options in Cantargia AB and has received honoraria from Novartis and Bristol-Myers Squibb. SM has received research funding from Novartis, Bristol-Myers and Squibb and Pfizer and honoraria from Novartis and Bristol-Myers and Squibb. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website .
Supplementary information
Rights and permissions
About this article
Cite this article
Landberg, N., Hansen, N., Askmyr, M. et al. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. Leukemia 30, 255–258 (2016). https://doi.org/10.1038/leu.2015.135
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.135
This article is cited by
-
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
Current Hematologic Malignancy Reports (2023)
-
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
British Journal of Cancer (2022)
-
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Stem Cell Research & Therapy (2021)
-
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
Leukemia (2021)
-
Die CML und das Problem der Stammzellpersistenz
InFo Hämatologie + Onkologie (2020)